Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,366 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 11,366 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01 | Direct | 7,800 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 16:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001453687-26-000039 · wk-form4_1767734365.xml · derivative · entry 2 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2036-01-01 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-26-000039 · wk-form4_1767734365.xml · nonDerivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,366 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 16:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $16.93 | $0.00 |
DisclosureSEC source: 0001453687-25-000015 · wk-form4_1736198338.xml · derivative · entry 2 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2035-01-01 Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 16:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-25-000015 · wk-form4_1736198338.xml · nonDerivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,766 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026. F2 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 17:05 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 228,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001453687-24-000020 · wk-form4_1704405920.xml · derivative · entry 2 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,000 Underlying: Common Stock · 228,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: This award will vest in 36 equal monthly installments, so that it shall be fully vested on January 2, 2027. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 17:05 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 178,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-24-000020 · wk-form4_1704405920.xml · nonDerivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | $0.93 Strike: $1.13 | $69,750.00 |
DisclosureSEC source: 0001453687-23-000086 · wk-form4_1700086723.xml · derivative · entry 3 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F3 · derivative.exercise_date: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001453687-23-000086 · wk-form4_1700086723.xml · derivative · entry 2 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F2 · price: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. F2 · derivative.exercise_date: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 17:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001453687-23-000086 · wk-form4_1700086723.xml · derivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2031-06-22 F1 · price: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 23, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. F1 · derivative.exercise_date: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 23, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:02 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000020 · wf-form4_167286972909668.xml · derivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:33 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001453687-22-000018 · wf-form4_164141836846044.xml · derivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 3, 2023. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 16:25 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 7,000 | $2.96 | $20,722.80 |
DisclosureSEC source: 0001453687-21-000163 · wf-form4_163882590930406.xml · nonDerivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.8999 to $2.9899. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2021 Filed Jul 9, 2021 16:21 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001453687-21-000090 · wf-form4_162586206787394.xml · derivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-06-22 F1 · derivative.exercise_date: The option vests in thirty-six (36) substantially equal monthly installments over three years following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.